Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc develops and manufactures therapeutic medical devices and healthcare technology for chronic diseases and procedural care. Its news commonly covers regulatory clearances and CE marks, product launches, clinical data, acquisitions, and financial results across cardiovascular, cardiac rhythm management, cranial and spinal technologies, surgical navigation, robotics, and ablation systems.
Recent company updates include the Stealth AXiS™ surgical system for planning, navigation, and robotics; the Affera™ mapping and ablation system with Sphere-9™ and Sphere-360™ catheters; the OmniaSecure™ defibrillation lead; and the completed CathWorks acquisition, including the FFRangio® System for coronary artery disease assessment.
Medtronic plc (NYSE:MDT) announced a $0.63 cash dividend for Q3 of fiscal 2022, marking a 9% increase from the previous year. This increase reinforces its position as a member of the S&P 500 Dividend Aristocrats, with 44 consecutive years of dividend growth. The dividend will be payable on January 14, 2022, to shareholders of record by December 22, 2021. Medtronic is recognized for its innovative healthcare solutions and has a workforce of over 90,000 globally.
Medtronic (NYSE:MDT) reported a second-quarter revenue of $7.847 billion, up 3% year-over-year, with organic growth of 2%. GAAP diluted EPS was $0.97, a 169% increase. Second-quarter U.S. revenue of $3.997 billion declined 1%, while emerging markets surged 20%. The company revised fiscal year 2022 organic revenue growth expectations to 7-8% from 9%. Despite challenges from COVID-19 and labor shortages affecting procedures, Medtronic remains optimistic about growth due to a strong pipeline and operational improvements.
Medtronic (NYSE:MDT) has received FDA 510(k) clearance for its PillCam™ Small Bowel 3 system, enabling remote endoscopy procedures through the PillCam SB3 @HOME program. This innovation allows patients to undergo telehealth procedures for detecting gastrointestinal issues such as Crohn's disease and obscure bleeding from home. The system captures approximately 50,000 images during the procedure, which are securely transmitted for diagnostic review, enhancing patient safety and convenience. This marks a significant development in remote healthcare technology, especially post-pandemic.
Medtronic plc (NYSE:MDT) announced four key executive appointments to enhance its healthcare technology leadership. Bob Hopkins becomes head of global strategy, Mei Jiang takes on the role of global digital innovation leader, while Harry 'Skip' Kiil and Mira Sahney will lead the Cranial and Spinal Technologies and Pelvic Health Operating Units, respectively. These appointments aim to bring diverse expertise and accelerate innovation in a rapidly evolving medical technology landscape, furthering Medtronic's mission to deliver transformative healthcare solutions.
Summary not available.
Medtronic plc (NYSE:MDT) will announce its financial results for Q2 FY2022 on November 23, 2021, at approximately 5:45 a.m. CST. The results will cover the quarter ending October 29, 2021. A video webcast to discuss these results will take place at 7:00 a.m. CST on the same day. Medtronic is scheduled to report its Q3 and Q4 results in February and May 2022, respectively. The company, based in Dublin, focuses on healthcare technology solutions, aiming to alleviate pain and restore health.
Summary not available.
Medtronic announced early data from its Intrepid transcatheter mitral valve replacement (TMVR) system at the TCT conference following FDA IDE approval for transfemoral access in the APOLLO trial. Early results show 100% survival and no strokes among the first 15 patients, with a median procedure time of 46 minutes and trace mitral regurgitation in all patients at 30 days. This delivery method may reduce procedural risks. The Intrepid system has been employed in over 350 patients globally, indicating significant interest in its potential for wider clinical use.
Medtronic (NYSE:MDT) announced positive five-year clinical results from the SURTAVI Trial for TAVR patients at intermediate risk. The trial revealed that TAVR with the CoreValve and Evolut platforms demonstrated comparable all-cause mortality rates (30.0% for TAVR vs. 28.7% for SAVR) and lower mean aortic valve gradients (8.6 mm Hg vs. 11.2 mm Hg), ensuring valve performance and safety. The study included 864 TAVR patients compared to 796 surgical patients, highlighting the long-term viability of TAVR in treating severe aortic stenosis.
Medtronic has presented findings from a Patient Preferences study on hypertension treatment at TCT 2021, revealing that patients are willing to accept interventions even with modest blood pressure reductions. The study showed that 76.5% would consider renal denervation (RDN) for a 10 mmHg decrease. Additionally, Medtronic launched the SPYRAL AFFIRM study, focusing on the safety and efficacy of RDN in patients with uncontrolled hypertension and comorbidities. The study will enroll 1,000 patients over three years and is part of a broader effort to establish RDN as a viable treatment option.